NIH_SPENDING_CATS: Behavioral and Social Science;HIV/AIDS;Pediatric;Prevention

ORG_CITY: STANFORD

ORG_DEPT: PEDIATRICS

ORG_NAME: STANFORD UNIVERSITY

PHR: PROJECT NARRATIVE To optimally support child health and development, research needs to be designed to account for the scale of disease burden and child mortality and shifts that occurs worldwide. The Pediatric Subspecialty Global Health Research T32 training program will capitalize on the significant resources that currently exist across the campus of Stanford University to provide dual fellowship training in a pediatric subspecialty combined with research focused on global child health, as well as completion of a Masters in Epidemiology and Clinical Research. This comprehensive program will train a new generation of pediatric subspecialty global health scientists equipped to advance the research agenda outlined in the NICHD Scientific Vision, including studies of the developmental origins of health and disease, pregnancy outcomes, behavior and cognition, and population dynamics at the global level.

PI_NAMEs: MALDONADO, YVONNE A. (contact)

PROGRAM_OFFICER_NAME: RUSSO, DENISE

PROJECT_TERMS: Childhood;Fellowship;global health

PROJECT_TITLE: Pediatric Global Health Subspecialty Fellowship


ADMINISTERING_IC: CA

ARRA_FUNDED: N

ED_INST_TYPE: OVERALL MEDICAL

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

ORG_CITY: HOUSTON

ORG_COUNTRY: UNITED STATES

ORG_DEPT: MISCELLANEOUS

ORG_FIPS: US

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

ORG_STATE: TX

PHR: NARRATIVE Immunotherapy for the treatment of cancer relies on the activity of specialized white blood cells called cytotoxic (or “killer”) T cells which are capable of eliminating tumors, provided they recognize specific targets on the tumor cell surface. Identifying these tumor-specific targets in cancer patients will allow for the design and administration of personalized immunotherapies with the potential to benefit or even cure these patients. The major goal of this grant proposal is to use specialize methodologies to identify novel and unconventional immunotherapeutic targets for melanoma, thus enabling the development of effective immunotherapeutic treatments for patients with these and other cancer types.

PI_NAMEs: HWU, PATRICK ;LIZEE, GREGORY A (contact)

PROGRAM_OFFICER_NAME: BOURCIER, KATARZYNA

PROJECT_TERMS: Antigen Presentation;Antigen Targeting;Antigens;Applications Grants;Bioinformatics;bioinformatics pipeline;BRAF gene;cancer immunotherapy;Cancer Patient;cancer therapy;cancer type;Categories;Cell surface;Cellular immunotherapy;Clinical;Cytolysis;cytotoxic;Cytotoxic T-Lymphocytes;Data;design;Detection;Development;Disease;DNA;driver mutation;Engineering;Epitopes;Foundations;Genetic;Goals;Human;Immune;immunogenic;immunogenicity;Immunotherapeutic agent;Immunotherapy;Infusion procedures;innovation;Interleukin-2;Intervention;Introns;Knowledge;Leukocytes;Malignant Neoplasms;MAP Kinase Gene;Mass Spectrum Analysis;Mediating;Melanoma;Melanoma Cell;Melanoma patient;Methodology;Methods;Minority;Mitogen-Activated Protein Kinases;multicatalytic endopeptidase complex;Nature;neoplastic cell;next generation;novel;Oncogenic;Pathway interactions;Patients;Peptide Vaccines;Peptides;personalized immunotherapy;Phosphopeptides;Post-Translational Protein Processing;Proteomics;Refractory;Reporting;Research;RNA Editing;RNA Splicing;Safety;Source;Specificity;success;T-Cell Receptor;T-Cell Receptor Therapy;T-Lymphocyte;Techniques;Therapeutic;therapeutic target;transcriptome sequencing;transcriptomics;Translating;tumor;Tumor Antigens;tumor specificity;Tumor-Infiltrating Lymphocytes;Vaccines;Work

PROJECT_TITLE: Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OTC-M(08)F]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Biotechnology;Emerging Infectious Diseases;Immunization;Immunotherapy;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Vaccine Related;Vector-Borne Diseases

ORG_CITY: PORTLAND

ORG_NAME: OREGON HEALTH & SCIENCE UNIVERSITY

ORG_STATE: OR

PHR: PROJECT NARRATIVE STING is a cellular signaling protein crucial to generating innate and adaptive immune responses against microbe-infected cells that can elicit beneficial vaccine outcomes when activated by adjuvants. We propose to use animal and in vitro models to characterize the molecular and immunological effects of a novel vaccine platform that incorporates virus-like particles containing internalized STING-inducing molecules. Results we generate will have a transformative impact on vaccine technology and our understanding of the biological role of STING and its immunotherapeutic potential as a pharmacologic target.

PI_NAMEs: DEFILIPPIS, VICTOR ROBERT (contact)

PROGRAM_OFFICER_NAME: DUPUY, LESLEY CONRAD

PROJECT_TERMS: Acceleration;adaptive immune response;adaptive immunity;Address;Adjuvant;Alpha Virus;Animals;Antibodies;Antigen-Presenting Cells;Antigens;Arboviruses;Biological;Cell Line;Cell Physiology;Cells;Cellular Immunity;Chemicals;Chikungunya virus;Clinical;clinical development;Cyclic GMP;Dinucleoside Phosphates;Disparity;DNA;draining lymph node;efficacy evaluation;emerging virus;Encapsulated;Enzymes;Exhibits;exosome;extracellular;Flavivirus;gene induction;Genes;Genome;Goals;Growth;Human;Immune;immune function;Immune response;Immune signaling;Immunity;immunogenic;Immunologic Stimulation;Immunological Models;Immunologics;immunoregulation;Immunotherapeutic agent;improved;In Vitro;in vitro Model;in vivo;in vivo Model;Injections;Innate Immune Response;Ligands;Link;Macaca mulatta;Mammals;Mediating;Methods;Microbe;Modeling;Molecular;mouse model;Mus;nonhuman primate;novel;novel vaccines;Outcome;pathogenic microbe;Pattern recognition receptor;Periodicity;pharmacologic;Phenotype;Predisposition;Process;Proteins;Purines;Reaction;recruit;response;RNA;Role;Safety;Signaling Protein;Site;small molecule;Stimulator of Interferon Genes;Structure;System;Technology;transcriptomics;Vaccination;vaccination outcome;Vaccine Adjuvant;vaccine efficacy;vaccine platform;Vaccines;Viral;Virion;Virus;Virus Replication;Virus-like particle;Zika Virus

PROJECT_TITLE: A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses

STUDY_SECTION: VID

STUDY_SECTION_NAME: Vaccines Against Infectious Diseases Study Section[VID]


FUNDING_MECHANISM: OTHER RESEARCH-RELATED

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Digestive Diseases;Orphan Drug;Pancreatic Cancer;Radiation Oncology;Rare Diseases

ORG_CITY: BOSTON

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

ORG_STATE: MA

PHR: Pancreatic ductal adenocarcinoma (PDAC) is an invasive and rapidly progressive malignancy that remains highly lethal despite recent therapeutic advances. There is an urgent and unmet clinical need for more reliable and accurate imaging tools to optimize delineation of the tumor and non-invasive evaluation of response to neoadjuvant chemoradiotherapy. The purpose of this study is to develop an image-guided paradigm using a novel collagen specific PET imaging probe to address these needs with the ultimate goal of improved management and clinical care of PDAC patients.

PI_NAMEs: ABDAR ESFAHANI, SHADI  (contact)

PROGRAM_OFFICER_NAME: RADAEV, SERGEY

PROJECT_TERMS: Abdomen;Accounting;Address;anatomic imaging;Animal Model;Appearance;Award;biomarker validation;Biopsy;cancer biomarkers;Cancer Etiology;Cancer Model;cancer type;care costs;Caring;Cessation of life;chemoradiation;Clinical;clinical biomarkers;clinical care;Clinical Management;Clinical Trials;Collagen;Collagen Type I;curative treatments;Data;Detection;Development;Diagnostic Procedure;Discipline of Nuclear Medicine;Disease;Dryness;Evaluation;Excision;experience;Fibrosis;fluorodeoxyglucose;Foundations;Future;General Hospitals;Goals;Grant;healthy volunteer;Histopathology;Human;human subject;Image;image guided;imaging biomarker;Imaging Device;imaging modality;imaging probe;improved;improved outcome;kinetic model;Kinetics;Knowledge;Magnetic Resonance Imaging;Malignant neoplasm of pancreas;Malignant Neoplasms;Managed Care;Massachusetts;Measurement;Measures;Mentors;Mentorship;Metabolism;Methods;molecular imaging;Monitor;Neoadjuvant Therapy;non-invasive imaging;novel;Operative Surgical Procedures;Outcome;Pancreas;pancreas imaging;Pancreatic Ductal Adenocarcinoma;pancreatic ductal adenocarcinoma model;Patients;Physicians;Plasma;Positron-Emission Tomography;pre-clinical research;Procedures;Process;Prognostic Factor;prognostication;programs;Pulmonary Fibrosis;Radiation;Radiation therapy;radiologist;Reproducibility;Research;Resectable;Resected;response;Sampling;Scientist;side effect;Signal Transduction;Solid;Specificity;Staging;standard of care;Surgeon;Testing;Therapeutic;Time;Tissues;Training;treatment optimization;treatment planning;treatment response;treatment strategy;tumor;Tumor Tissue;Tumor Volume;uptake;X-Ray Computed Tomography

PROJECT_TITLE: Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal Adenocarcinoma

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Career Development Study Section (J)[NCI-J]


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Brain Disorders;Cancer;Chronic Pain;Epilepsy;Neurodegenerative;Neurosciences;Pain Research;Pediatric;Peripheral Neuropathy

ORG_CITY: Chicago

ORG_NAME: NORTHWESTERN UNIVERSITY

ORG_STATE: IL

PHR: Project Narrative When the concentration of -aminobutyric acid (GABA) diminishes in the brain, convulsions can occur and neuropathic pains can prevail. Inhibition of GABA aminotransferase raises GABA levels and can terminate convulsions and ease neuropathic pain. We propose to design, synthesize, study inactivation mechanisms, and evaluate in vitro and in vivo new compounds to inactivate GABA aminotransferase.

PI_NAMEs: SILVERMAN, RICHARD B (contact)

PROGRAM_OFFICER_NAME: LEENDERS, MIRIAM

PROJECT_TERMS: 2 year old;4-Aminobutyrate aminotransferase;abuse liability;Acids;Active Sites;Adult;Adverse effects;Affect;Alanine Transaminase;alternative treatment;American;Aminobutyric Acids;analog;Anticonvulsants;Aspartate Transaminase;Binding;Blindness;Blood - brain barrier anatomy;blood-brain barrier crossing;blood-brain barrier penetration;boys;Brain;Cancer Patient;Carboxylic Acids;Cell Survival;chemotherapy;chemotherapy induced neuropathy;Chemotherapy-induced peripheral neuropathy;Chronic;Classification;comparative;Complex;Computer Models;Convulsions;Crystallography;cytotoxicity;design;Diffusion;Disease;Dose;driving force;Drug Kinetics;Effectiveness;efficacy evaluation;Enzymes;Epilepsy;FDA approved;Focal Seizure;gamma-Aminobutyric Acid;Glutamate Decarboxylase;Glutamates;Glutamic Acid;Goals;improved;In Vitro;in vivo;Indiana;Infantile spasms;inhibitor;Intractable Epilepsy;mental state;Modeling;Modification;Motor Ataxias;Motor Seizures;National Institute of Neurological Disorders and Stroke;neoplastic cell;neural;Neurons;Neurotransmitters;Normal Cell;novel strategies;Ornithine-oxo-acid aminotransferase;ovid;Paclitaxel;Pain;Pain management;painful neuropathy;Patients;pediatric patients;Penetration;Pharmaceutical Preparations;Population;pre-clinical;Prodrugs;professor;programs;Property;prophylactic;Pyridoxal Phosphate;Rattus;Recurrence;Refractory;Regulation;Research;Rewards;Risk;Schedule;screening;screening program;Sedation procedure;Seizures;side effect;Spinal;Structure;succinic semialdehyde;Testing;Therapeutic;Transaminases;United States National Institutes of Health;Universities;Vigabatrin

PROJECT_TITLE: New Inactivators of GABA Aminotransferase for Epilepsy and Neuropathic Pain

STUDY_SECTION: MSFA

STUDY_SECTION_NAME: Macromolecular Structure and Function A Study Section[MSFA]


ADMINISTERING_IC: AR

ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Clinical Research;Physical Rehabilitation;Rehabilitation

ORG_DEPT: BIOMEDICAL ENGINEERING

PHR: Project Narrative A fundamental challenge in physical medicine and rehabilitation has long been measuring muscle force and stiffness, yet there are no rigorous methods for doing so noninvasively. Ultrasound elastography is a promising tool but it remains unclear precisely what this tool measures when applied to muscle. The objectives of this proposal are to determine how elastography is sensitive to changes in muscle force and stiffness during conditions encountered in everyday activities, and to test a novel approach for uniquely determining these two important quantities from ultrasound measurements.

PI_NAMEs: PERREAULT, ERIC JON (contact)

PROGRAM_OFFICER_NAME: LINDHURST, MARJORIE JEAN

PROJECT_TERMS: 3D Print;Animal Model;Architecture;Area;Assessment tool;Biocompatible Materials;Biomechanics;Cerebral Palsy;Clinic;Clinical;clinically relevant;Complex;Dependence;Disease;elastography;Elements;Environment;experimental study;Felis catus;Funding;Goals;Harvest;Health;Human;Impairment;improved;Individual;innovation;Intuition;Measurement;Measures;mechanical properties;Methods;Modeling;Modulus;motor behavior;motor control;motor disorder;Movement;Movement Disorders;Muscle;Muscle Fibers;Muscle function;muscle stiffness;muscle stress;muscular structure;Musculoskeletal Diseases;Musculoskeletal Equilibrium;musculoskeletal injury;neural;novel;novel strategies;Pain;Pathologic;Patients;Pattern;Physical Medicine;Physical Rehabilitation;Posture;Property;Protocols documentation;Rehabilitation therapy;Resistance;response;shear stress;Skeleton;Soleus Muscle;Stress;Stretching;Stroke;Techniques;Testing;Tissues;tool;ultrasound;Variant

PROJECT_TITLE: Noninvasive tools for assessing muscle structure and function

STUDY_SECTION: MFSR

STUDY_SECTION_NAME: Motor Function, Speech and Rehabilitation Study Section[MFSR]


ADMINISTERING_IC: HD

ED_INST_TYPE: SCHOOLS OF MEDICINE

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Autism;Behavioral and Social Science;Brain Disorders;Childhood Obesity;Clinical Research;Clinical Trials and Supportive Activities;Health Services;Intellectual and Developmental Disabilities (IDD);Mental Health;Networking and Information Technology R&D (NITRD);Nutrition;Obesity;Pediatric;Prevention;Telehealth

ORG_CITY: LA JOLLA

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

ORG_STATE: CA

PHR: NARRATIVE This project will compare the efficacy of a parent-only treatment for children with both autism spectrum disorder (ASD) and overweight or obesity (OW/OB) compared to a health education active comparator. Information from this study could advance the standard of practice for children with ASD, and will provide a tailored intervention for children with ASD and OW/OB.

PI_NAMEs: BOUTELLE, KERRI N (contact)

PROGRAM_OFFICER_NAME: KAU, ALICE S

PROJECT_TERMS: acceptability and feasibility;active comparator;Adaptive Behaviors;Adolescent;adolescent with autism spectrum disorder;Adult;Affect;Aftercare;Age;autism spectrum disorder;autism symptoms;autistic children;Behavior;Behavior Therapy;Body mass index;Body Size;Body Weight decreased;Child;Child Rearing;Childhood;Clinical;comparative efficacy;Consumption;Control Groups;cost;Data;Development;Diagnosis;Dietary intake;Educational Status;effective therapy;efficacious intervention;Exclusion;executive function;Family;follow-up;Gender;Goals;Health;Health education;Health Personnel;Height;Heterogeneity;High Prevalence;individualized medicine;Intervention;intervention cost;intervention program;Language;Mediator;Modeling;Obesity;obesity in children;obesity treatment;Outcome;Overweight;Parenting Education;parenting intervention;Parents;Physical activity;Pilot Projects;pilot test;Play;Population;programs;psychosocial;Public Health;Randomized;randomized trial;recruit;Reporting;Research;Research Personnel;Role;satisfaction;Self Efficacy;Severities;skills;Symptoms;telehealth;Time;treatment group;treatment program;treatment response;United States;Vegetables;Vulnerable Populations;Weight;weight loss program;Youth

PROJECT_TITLE: Telehealth Parent-Only Treatment for Youth with Autism Spectrum Disorder and Overweight/Obesity

STUDY_SECTION: LCBH

STUDY_SECTION_NAME: Lifestyle Change and Behavioral Health Study Section[LCBH]


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Bioengineering;Biotechnology

ORG_CITY: TAMPA

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: UNIVERSITY OF SOUTH FLORIDA

ORG_STATE: FL

PHR: Project Narrative Advances in computational and experimental protein engineering have ushered in a new era of biomolecule development with both fundamental and applied aims, but current approaches lack the ability to develop and study synthetic receptors and inhibitory molecules in high throughput. We propose to develop protein engineering platforms for robust inhibitor development, for studying synthetic receptors, and for a combined computational and experimental pipeline to engineer and study natural molecules. Once developed, these platforms will be applied to study fundamental questions in cell signaling, in development of disease pathologies, and in biomolecular sequence-function and structure-function relationships.

PI_NAMEs: STERN, LAWRENCE A (contact)

PROGRAM_OFFICER_NAME: FABIAN, MILES

PROJECT_TERMS: Area;Basic Science;Binding Proteins;Biological;Clinical Sciences;Communities;cost;design;Development;Directed Molecular Evolution;Disease;empowerment;Engineering;Enzymes;Goals;high throughput screening;improved;Individual;inhibitor;Libraries;Measurable;Mutagenesis;mutant;Mutation;Pathology;Pathway interactions;pressure;Process;Proliferating;Protein Engineering;protein function;Proteins;rational design;receptor;receptor function;response;Role;screening;Signal Transduction;small molecule;Structure-Activity Relationship;Surface;synthetic biology;synthetic protein;Techniques;Work;Yeasts

PROJECT_TITLE: High-Throughput Platforms to Study Synthetic Receptors, Natural Molecules, and New Pathway Inhibitors

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-BCMB-E(55)]


ED_INST_TYPE: SCHOOLS OF PHARMACY

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

ORG_CITY: CHAPEL HILL

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

ORG_STATE: NC

PHR: NARRATIVE As our understanding of how molecular structure affects biological processes increases, interest in performing research at the boundary of chemistry and biology has increased. The range of learning at this interface is large and poses great challenges for educating emerging biomedical scientists who incorporate chemistry into their work. We seek to establish a comprehensive training program that will empower young people beginning their careers in this field at the University of North Carolina at Chapel Hill.

PI_NAMEs: AUBE, JEFFREY  (contact)

PROGRAM_OFFICER_NAME: PAUL, MOUSHUMI

PROJECT_TERMS: Biology;Chemicals;Training Programs

PROJECT_TITLE: UNC Chemical Biology Interface Training Program

STUDY_SECTION: TWD

STUDY_SECTION_NAME: Training and Workforce Development Study Section - B[TWD-B]


ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

NIH_SPENDING_CATS: Bioengineering;Cancer

ORG_DEPT: CHEMISTRY

PHR: RELEVANCE The diagnosis and treatment of cancer begins with discovering the ways cancer cells differ from normal cells, and how those differences allow cancer cells to grow and spread around the body. Glycoproteins called mucins vary widely in abundance and composition between cancer and normal cells. In this project we will develop tools to characterize the molecular structures of cancer mucins and study why they change in cancer, with an eye toward developing new diagnostic and therapeutic agents.

PI_NAMEs: BERTOZZI, CAROLYN  (contact)

PROGRAM_OFFICER_NAME: MAZURCHUK, RICHARD V

PROJECT_TERMS: Adhesions;Algorithm Design;Algorithms;Binding;Biochemical;Biochemical Pathway;Biological;Biological Process;cancer biomarkers;cancer cell;cancer diagnosis;cancer therapy;Cell Line;Cell Survival;Cells;Chemicals;Clinical;Code;Development;Diagnosis;Disease Progression;Engineering;Enzymes;Flow Cytometry;Funding;Glycocalyx;Glycopeptides;Glycoproteins;glycoproteomics;glycosylation;Goals;host microbiota;ionization technique;Isotopes;Link;Malignant neoplasm of ovary;Malignant Neoplasms;Maps;Mass Spectrum Analysis;Measurement;Methods;Molecular;Molecular Conformation;Molecular Profiling;Molecular Structure;mucinase;Mucins;new therapeutic target;Normal Cell;novel diagnostics;novel therapeutics;Oncogenes;Pathway interactions;Pattern;Peptide Hydrolases;polypeptide;Polypeptide N-acetylgalactosaminyltransferase;Polysaccharides;Protein Glycosylation;Proteomics;Reagent;receptor binding;Sampling;Site;Structure;tandem mass spectrometry;technology development;Therapeutic Agents;Tissue Stains;Tissues;tool;tumor progression;Visualization;Western Blotting;Work

PROJECT_TITLE: Chemical Glycoproteomics

STUDY_SECTION: SBCA

STUDY_SECTION_NAME: Synthetic and Biological Chemistry A Study Section[SBCA]


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

PHR: Project Narrative: Microscopic colitis is an inflammatory disorder of the gastrointestinal tract and a common cause of chronic diarrhea and fecal incontinence in older adults. The goals of this proposal are to identify pharmacologic determinants of microscopic colitis, to characterize the composition and function of the gut microbiota with disease activity, and to examine the interplay between pharmacologic risk factors and the gut microbiota in relation to risk of microscopic colitis. The public health benefits of the study findings include informing clinical guidelines for management of microscopic colitis and providing in-depth examination of how commonly prescribed medications in interaction with the gut microbiota may predispose older adults to gut inflammation.

PI_NAMEs: KHALILI, HAMED  (contact)

PROGRAM_OFFICER_NAME: FLORES, ROBERTO L

PROJECT_TERMS: Address;Affect;Aging;aging population;Anaerobic Bacteria;Anti-Hypertensive Agents;Anti-Inflammatory Agents;Area;Bacteria;bile salts;biobank;Biological Markers;Blood;Blood specimen;burden of illness;Butyrates;Chronic;Chronic diarrhea;Clinical;cohort;Colitis;Colonoscopy;Communities;Computational Biology;Computing Methodologies;Data;Development;Diagnosis;Digestive System Disorders;Disease;Disease remission;Drug Prescriptions;dysbiosis;Environmental Exposure;Environmental Risk Factor;Epidemiology;Escherichia coli;Etiology;Evaluation;Exogenous Hormone Therapy;Fatty Acids;FDA approved;Fecal Incontinence;Feces;follow-up;Foundations;Functional disorder;gastrointestinal;Gastrointestinal Diseases;Genetic;Goals;Grant;Guidelines;gut inflammation;gut microbiome;gut microbiota;Health Benefit;Histopathology;hormone therapy;Immune response;Incidence;Individual;Inflammatory;Inflammatory Bowel Diseases;inhibitor;innovation;insight;Large Intestine;Link;Lipids;Mediating;Mediation;Medical;metagenomic sequencing;Microbe;microbial community;microbial signature;microbiome;microbiome research;microbiome signature;microbiota;microbiota profiles;Microscopic;Microscopic Colitis;mortality;multidisciplinary;Non-Steroidal Anti-Inflammatory Agents;novel;older adult;Oral;Oxidative Stress;Oxidative Stress Pathway;Pathogenesis;Pathology;Patients;Pharmaceutical Preparations;Pharmacoepidemiology;pharmacologic;Phase;Phenotype;Polypharmacy;Population;Production;Proton Pump Inhibitors;Public Health;Publications;Pump;Quality of life;Questionnaires;Recommendation;Recurrent disease;Refractory Disease;Research;Research Design;Risk;Risk Factors;Role;Ruminococcus;stool sample;Streptococcus;Structure;Sweden;Testing;Volatile Fatty Acids;Work

PROJECT_TITLE: Medications, the gut microbiota, and risk of microscopic colitis

STUDY_SECTION: KNOD

STUDY_SECTION_NAME: Kidney, Nutrition, Obesity and Diabetes Study Section[KNOD]


FUNDING_MECHANISM: RESEARCH CENTERS

ORG_CITY: NEW YORK

ORG_NAME: SLOAN-KETTERING INST CAN RESEARCH

ORG_STATE: NY

PHR: OVERALL NARRATIVE There are currently no approved or effective therapies for most acute myeloid leukemia (AML) subtypes. Our proposed SPORE in Leukemia has the potential to develop practice-changing approaches for AML evaluation and management and directly lead to improved patient outcomes for AML. We will achieve this by focusing on developing novel targeted and immune therapies for AML and by studying sensitivity and resistance to established/emerging AML treatments using clinical samples and state-of-the-art patient tumor model systems.

PI_NAMEs: ABDEL-WAHAB, OMAR  (contact);STEIN, EYTAN

PROGRAM_OFFICER_NAME: KUZMIN, IGOR A

PROJECT_TERMS: Acute Myelocytic Leukemia;Address;Adult;adverse outcome;Antigens;Area;Bioinformatics Shared Resource;Biological;Biological Models;biomarker identification;Biometry;cancer genetics;career;Cessation of life;chimeric antigen receptor T cells;Classification;Clinic;Clinical;Clinical Data;Clinical Investigator;Clinical Management;Clinical Trials;Collaborations;collaborative approach;Complex;Computational Biology;data integration;data platform;Development;Disease;DNA Sequence Alteration;Dysmyelopoietic Syndromes;early phase clinical trial;Eastern Cooperative Oncology Group;effective therapy;Ensure;Enzymes;Epigenetic Process;Evaluation;FLT3 gene;FLT3 inhibitor;functional genomics;Future Generations;Genetic;Genomic approach;genomic biomarker;Genomics;Goals;Hematopoietic stem cells;high risk;Human;human tissue;IL18 gene;Immune;Immune Targeting;Immunotherapeutic agent;Immunotherapy;improved;improved outcome;Incidence;Industry;inhibitor;inhibitor therapy;innovation;insight;Institution;Karyotype;Ketoglutarate Dehydrogenase Complex;Lead;leukemia;leukemia treatment;leukemic stem cell;Maintenance;Malignant Neoplasms;Medical;medical schools;Memorial Sloan-Kettering Cancer Center;Mentorship;Metabolic;Molecular;Molecular Abnormality;molecular pathology;molecular subtypes;Molecular Target;molecular targeted therapies;Morbidity - disease rate;multidisciplinary;mutant;Mutation;new therapeutic target;novel;novel marker;novel strategies;novel therapeutic intervention;novel therapeutics;Pathogenesis;Pathway interactions;Patient-Focused Outcomes;Patients;Pharmacologic Substance;Pharmacotherapy;Phase I/II Clinical Trial;Pilot Projects;pre-clinical;Pre-Clinical Model;preclinical study;predicting response;premature;Preparation;Prognosis;programs;Protein Inhibition;Protein-Arginine N-Methyltransferase;Recurrence;relapse patients;Reproduction spores;Research;Research Personnel;Research Project Grants;Resistance;resistance mechanism;Resource Sharing;response biomarker;Risk;RNA Splicing;Safety;Sampling;Southwest Oncology Group;Spliceosomes;stem cell biomarkers;Survival Rate;targeted treatment;Therapeutic;therapeutic target;therapy resistant;Therapy-Related Acute Myeloid Leukemia;TP53-mutant acute myeloid leukemia;Translating;translational potential;Translational Research;Treatment Efficacy;treatment response;tumor;United States Food and Drug Administration;Universities

PROJECT_TITLE: The Memorial Sloan Kettering Cancer Center SPORE in Leukemia


ED_INST_TYPE: EARTH SCIENCES/RESOURCES

NIH_SPENDING_CATS: Genetics;Human Genome

ORG_CITY: ITHACA

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: CORNELL UNIVERSITY

PHR: PROJECT NARRATIVE This program seeks to understand how human enzymes prevent the loss of genomic integrity. We will learn how organization of key homologous recombination intermediates promote DNA sequence alignment, and chromosome template choice.

PI_NAMEs: CRICKARD, JOHN BROOKS (contact)

PROGRAM_OFFICER_NAME: MACARTHUR, LINDA

PROJECT_TERMS: Alleles;Biochemical;Biochemistry;Chromatin;Chromosomes;Complex;Dangerousness;Data;Development;DNA Damage;DNA Double Strand Break;DNA Repair;DNA Sequence;Double Strand Break Repair;Enzymes;experimental study;Exposure to;Genes;genetic information;Genome;genome integrity;Goals;Growth;homologous recombination;Human;Human Activities;Learning;Maintenance;Malignant Neoplasms;Meiosis;Mitosis;Mitotic;Modeling;Molecular;Molecular Biology;Motor;Organism;Pathway interactions;presynaptic;prevent;programs;Proteins;RAD54L gene;Regulation;repaired;Research Proposals;Saccharomyces cerevisiae;segregation;Sequence Alignment;Sequence Homologs;single molecule;Sister Chromatid;Variant;Work

PROJECT_TITLE: Molecular Mechanisms of Human Homologous Recombination

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-I(55)R]


NIH_SPENDING_CATS: Cancer;Hematology;Rare Diseases

PHR: PROJECT NARRATIVE The Administrative Core provides centralized scientific, managerial, and administrative oversight of the SPORE in Leukemia at Memorial Sloan Kettering Cancer Center. The core will leverage institutional resources and coordinate institutional interactions as well as administrative, fiscal, regulatory, and data management activities to facilitate efficient achievement of the translational research objectives.

PI_NAMEs: ABDEL-WAHAB, OMAR  (contact)

PROJECT_TERMS: Achievement;Advocate;Biometry;career;Clinical;clinical database;Clinical Research;Collaborations;Communication;Communities;data management;Data Management Resources;data sharing;Decision Making;Development;editorial;Education;Ensure;Equity;Extramural Activities;Financial Support;Fostering;General Population;Genomics;Grant;Health Services Accessibility;Human Resources;Individual;Infrastructure;Institution;leukemia;Manuscripts;Medical;meetings;Memorial Sloan-Kettering Cancer Center;Monitor;National Cancer Institute;Occupational activity of managing finances;outreach;patient oriented;Patients;Pilot Projects;programs;Publications;Regulation;Reporting;Research;Research Personnel;Research Project Grants;Resources;Services;Support System;Training;translational progress;Translational Research

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Genetics;Hematology;Human Genome;Networking and Information Technology R&D (NITRD);Orphan Drug;Rare Diseases

PHR: PROJECT NARRATIVE The Genomics Core of the MSK SPORE in Leukemia brings together unique expertise in computational biology and modeling of genomic data to support generation, analyses, and interpretation of data generated in the research projects of the Leukemia SPORE. Our major aims are to deliver mechanistic insights into the biology, disease progression, and treatment response of AML. Our vision is to deliver data-driven and evidence-based research that will guide development of diagnostic biomarkers, disease surveillance tools, and, importantly, biologically-informed therapeutic interventions to include target identification, target validation, and preclinical model development.

PI_NAMEs: PAPAEMMANUIL, ELLI  (contact)

PROJECT_TERMS: Address;analytical method;Bioinformatics;Biological;Biological Assay;Biological Specimen Banks;Biology;Biometry;Biostatistics Core;Cells;Clinical Data;Clustered Regularly Interspaced Short Palindromic Repeats;Computational Biology;Computer Models;Consult;Credentialing;Data;Data Analyses;data format;Deposition;Development;diagnostic biomarker;diagnostic development;Disease Progression;Disease Surveillance;Ensure;Epigenetic Process;epigenomic profiling;evidence base;experience;Experimental Designs;Formulation;functional genomics;Generations;Genetic;Genetic Transcription;genome-wide;genomic data;genomic profiling;genomic tools;Genomics;Goals;Human;Immunophenotyping;insight;laboratory experiment;Leadership;leukemia;Manuscripts;member;Memorial Sloan-Kettering Cancer Center;Mission;model development;Modeling;Molecular;mouse model;Mus;new therapeutic target;Patients;Pilot Projects;Pre-Clinical Model;public repository;Publications;Reporting;Research;Research Design;Research Personnel;Research Project Grants;Resistance;response;Sample Size;Sampling;Science;screening;small hairpin RNA;synergism;Techniques;Therapeutic;Therapeutic Intervention;therapy resistant;Tissues;tool;translational goal;treatment response;Validation;Vision;Work;Writing

PROJECT_TITLE: Core 1: Genomics


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Childhood Leukemia;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: NARRATIVE The development of more effective therapies for cancer requires preclinical tumor models that closely mimic the diseases being studied. The Biospecimen Core brings together specialized expertise in animal and patient- derived tumor modeling to create AML-specific tumor models and to test new strategies to treat AML patients.

PI_NAMEs: DE STANCHINA, ELISA  (contact)

PROJECT_TERMS: Acceleration;Acute Myelocytic Leukemia;Animals;Autologous;biobank;Bioinformatics;Biological Products;Biological Specimen Banks;Biometry;Blood;Blood specimen;Bone Marrow;cancer therapy;Cell Therapy;chimeric antigen receptor T cells;Clinical;clinical translation;clinically relevant;co-clinical trial;Collaborations;combinatorial;Combined Modality Therapy;Communities;Complex;Consultations;Data;Databases;Dedications;design;Development;Disease;Disease Management;DNA;Doctor of Philosophy;Documentation;effective therapy;efficacy study;efficacy testing;Ensure;Freezing;Gene Expression Profiling;Generations;Genetic study;Genetically Engineered Mouse;Genomics;Guidelines;Health Insurance Portability and Accountability Act;Hematology;Histologic;Hospital Units;Hospitals;Human;human tissue;IL18 gene;Immunocompromised Host;Implant;in vivo;in vivo Model;Infrastructure;inhibitor;Institutional Review Boards;Karyotype;Label;Leadership;leukemia;leukemia treatment;Memorial Sloan-Kettering Cancer Center;Mission;Modeling;Molecular;Mus;mutant;novel;novel therapeutics;Nucleic Acids;Oncology;participant enrollment;Pathology;patient privacy;Patients;Play;pre-clinical;Pre-Clinical Model;preclinical development;preclinical efficacy;preclinical trial;Process;Proteins;Protocols documentation;Recording of previous events;relational database;Research;Research Personnel;Research Project Grants;Resistance;Resource Sharing;Resources;RNA;RNA Splicing;Role;Safety;sample collection;Sampling;Services;Specimen;Standardization;Support Groups;Testing;Therapeutic;Therapeutic Research;Therapeutic Studies;therapy development;therapy resistant;tibia;Tissue Banks;Tissue Model;Tissues;Toxic effect;Toxicology;Translational Research;Translations;Transplantation;Treatment Efficacy;Tube;tumor;Whole Blood;Xenograft procedure

PROJECT_TITLE: Core 2: Biospecimen


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Genetics;Hematology;Human Genome;Rare Diseases

PHR: PROJECT NARRATIVE The Biostatistics Core will provide direct support for study design, rigorous statistical methods, and timely execution of data analysis for all research projects and developmental projects in the MSK Leukemia SPORE.

PI_NAMEs: GONEN, MITHAT  (contact)

PROJECT_TERMS: Address;analytical method;Bioinformatics;Biological Specimen Banks;Biometry;Biostatistics Core;Clinical Data;Clinical Research;clinical trial analysis;Consult;Data;Data Analyses;Data Analytics;data format;Databases;Dedications;Deposition;design;Development;Ensure;experience;Experimental Designs;Formulation;genome repository;genomic data;Genomics;Goals;Graph;Hematologic Neoplasms;human tissue;Individual;Laboratories;laboratory experiment;Leadership;leukemia;Manuscripts;member;Memorial Sloan-Kettering Cancer Center;Methodology;Modification;Molecular;Monitor;Nature;novel;Preparation;public repository;Publications;Reporting;Reproducibility;Reproduction spores;Research;Research Design;Research Personnel;Research Project Grants;Role;Sample Size;Science;Statistical Data Interpretation;Statistical Methods;System;translational goal;Validation;Work;Writing

PROJECT_TITLE: Core 3: Biostatistics


NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: NARRATIVE The identification of IDH1/IDH2 mutations in acute myeloid leukemia (AML) led to the development and approval of the first small molecule IDH1 (ivosidenib) and IDH2 (enasidenib) inhibitors for IDH1/2 mutant AML; however not all patients respond to IDH1/2 inhibition. We will use preclinical studies and analysis of primary samples from patients treated with IDH1/2 inhibitors to delineate molecular predictors of sensitivity and resistance to IDH inhibitors, and test novel combination therapeutic approaches to increase therapeutic efficacy in IDH1/2-mutant AML. The goal is to use this insight to test new therapeutic approaches in mechanism-based clinical trials aimed to improve outcomes in this molecularly defined AML subset.

PI_NAMEs: LEVINE, ROSS L (contact)

PROJECT_TERMS: Acute Myelocytic Leukemia;Alleles;Biological Assay;Chemotherapy-Oncologic Procedure;Clinical;Clinical Research;Clinical Trials;Combined Modality Therapy;Core Facility;Coupled;Credentialing;Development;Disease;Dose;Enrollment;FLT3 gene;FLT3 inhibitor;Genes;Genetic study;Genomics;Genotype;Goals;improved outcome;In complete remission;inhibitor;inhibitor therapy;insight;Investigation;Isocitrates;leukemia;Memorial Sloan-Kettering Cancer Center;Modeling;Molecular;mouse model;mutant;Mutate;Mutation;novel;novel therapeutic intervention;novel therapeutics;Pathogenesis;Pathway interactions;patient subsets;Patients;pre-clinical;preclinical study;prevent;programs;Recurrence;Refractory;Relapse;relapse patients;Research Project Grants;Resistance;resistance mechanism;response;Role;Sampling;Science;Signal Transduction;small molecule;targeted treatment;Testing;Therapeutic;Therapeutic Trials;therapy resistant;Treatment Efficacy;Validation

PROJECT_TITLE: Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)–mutant acute myeloid leukemia (AML)


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: NARRATIVE Approximately 10% of cases of acute myeloid leukemia (AML) have a complex karyotype (CK), meaning that the cancer displays 3 or more chromosomal abnormalities. These CK-AML patients face a dismal prognosis, as there are no effective treatment options. In this project, innovative genetic and modeling approaches will be used to better characterize human AML and to discover and validate targets for much-needed, novel therapies.

PI_NAMEs: LOWE, SCOTT W. (contact)

PROJECT_TERMS: 17p;actionable mutation;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Address;Animal Model;antileukemic activity;Antitumor Response;Biological;Cancer Model;candidate validation;Cell Differentiation process;Cell Line;Cessation of life;Chemoresistance;chemotherapy;Chromatin;chromosome 5q loss;Chromosome abnormality;Chromosomes;Clinical;Clinical Trials;cohort;Collaborations;Complex;cost;Cytogenetic Analysis;Data;Dependence;Development;Diagnosis;diagnostic accuracy;digital;Disease;disease model;Drug Targeting;effective therapy;Enzymes;Epigenetic Process;Event;Face;FLT3 gene;Frequencies;Gene Expression;Genetic;Genetic Transcription;Genetically Engineered Mouse;Genome;Genomics;Genotype;Human;human disease;human model;improved;inhibitor;innovation;insight;JAK2 gene;Karyotype;Karyotype determination procedure;Ketoglutarate Dehydrogenase Complex;leukemia;leukemia treatment;Malignant Neoplasms;Memorial Sloan-Kettering Cancer Center;Metabolism;Methods;Modeling;Molecular;mouse model;mutant;Mutation;Mutation Analysis;new therapeutic target;next generation sequencing;novel;novel therapeutic intervention;novel therapeutics;Oncogenes;Oncogenic;Oncoproteins;Outcome;Pathogenesis;patient derived xenograft model;Patient-Focused Outcomes;Patients;pharmacologic;pre-clinical;Pre-Clinical Model;preclinical study;Prognosis;programs;Proliferating;Proteins;Recurrence;Research;Research Personnel;Resistance;Resolution;Resources;Safety;Sampling;self-renewal;small molecule inhibitor;Solid;Specimen;Study models;System;Testing;Therapeutic;therapeutic development;therapeutic target;therapeutically effective;tool;TP53 gene;transcriptome;transcriptome sequencing;tumor;Tumor Suppressor Genes;Tumor Suppressor Proteins;tumorigenic;whole genome;Work

PROJECT_TITLE: Project 2: Defining and exploiting genetic dependencies in complex karyotype AML


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Orphan Drug;Rare Diseases

PHR: NARRATIVE We recently found that inhibiting enzymes called protein arginine methyltranserases (PRMTs) may be an effective treatment for leukemia. We propose to examine how patients treated with PRMT inhibitors respond at the molecular level, and to identify predictors of response such as genetic mutations in cancer cells, which could help improve the efficacy of this therapy. PRMT inhibitors are now entering early phase clinical trials for other cancers and we expect this project to facilitate testing of these drugs in leukemia.

PROJECT_TERMS: acute leukemia cell;Acute Myelocytic Leukemia;antagonist;anti-cancer;Arginine;Biological Markers;cancer cell;cancer type;Cell Death;cell growth;Cell Line;Cells;Chronic Lymphocytic Leukemia;Clinical Trials;Complex;cytotoxic;Data;Dependence;Development;DNA Sequence Alteration;Drug Screening;drug testing;Dysmyelopoietic Syndromes;early phase clinical trial;effective therapy;efficacy evaluation;Enzyme Inhibition;Enzymes;Epigenetic Process;epigenome;Evaluation;Family;Gene Expression;Genes;Genetic;Heterozygote;Histones;improved;In Vitro;in vivo;inhibitor;leukemia;leukemia treatment;Leukemic Cell;Lymphoblastic Leukemia;Malignant Neoplasms;Mediating;Memorial Sloan-Kettering Cancer Center;Methylation;Molecular;mRNA Precursor;mutant;Mutation;Myelogenous;Myeloid Leukemia;Non-Hodgkin's Lymphoma;participant enrollment;Patients;Pharmaceutical Preparations;Phase I Clinical Trials;Phase I/II Clinical Trial;Phase I/II Trial;preclinical study;predicting response;predictive marker;Proliferating;protein arginine methyltransferase 2;Protein Inhibition;Protein-Arginine N-Methyltransferase;Proteins;Proteome;Refractory;Research;response;RNA Splicing;Safety;Sampling;small hairpin RNA;small molecule;Solid Neoplasm;Spliceosome Assembly Pathway;Spliceosomes;Therapeutic;therapeutic target;Time;Toxic effect;Treatment Efficacy;Work;Xenograft procedure

PROJECT_TITLE: Project 3:  Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Hematology;Immunotherapy;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Nonembryonic - Non-Human

PHR: NARRATIVE There is a critical need to develop therapies to eliminate leukemia-stem cells (LSCs) as a treatment for acute myeloid leukemia (AML). To this end, we have developed a novel chimeric antigen receptor (CAR) T cell platform targeting CD371, a cell surface marker present on the vast majority of AML cells and LSCs but absent from normal hematopoietic stem cells. We will determine the safety and efficacy of CD371-targeted, IL18- secreting CAR T cells in patient-derived xenografts models and by conducting a phase I clinical trial in relapsed/refractory AML patients.

PI_NAMEs: BRENTJENS, RENIER JOSEPH (contact)

PROJECT_TERMS: Acute leukemia;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Address;Adult;Aftercare;anti-tumor immune response;Antigen Targeting;Antigens;Antitumor Response;cancer cell;CAR T cell therapy;CD19 gene;Cell surface;Characteristics;Chemoresistance;chemotherapy;chimeric antigen receptor T cells;Clinical;Clinical Treatment;Correlative Study;cytokine;Development;Disease;Disease Marker;Disease remission;efficacy evaluation;Goals;Hematopoiesis;Hematopoietic stem cells;Human;IL18 gene;immune cell infiltrate;immune clearance;immune reconstitution;Immune response;Immune Targeting;immunogenicity;Immunophenotyping;improved;Incidence;Investigational Therapies;Large-Cell Lymphomas;leukemia;leukemia/lymphoma;leukemic stem cell;Maximum Tolerated Dose;Mediating;Memorial Sloan-Kettering Cancer Center;Minority;Myeloid Cells;Natural regeneration;neoplastic cell;novel;Outcome;Pathologic;patient derived xenograft model;Patients;Phase I Clinical Trials;pre-clinical;Recurrent disease;Refractory;Regimen;Relapse;Remission Induction;response;response biomarker;Safety;safety assessment;Secondary to;Survival Rate;T cell response;T-Lymphocyte;Testing;Therapeutic;therapy development;Toxic effect;Transplantation;Treatment outcome;tumor;tumor microenvironment;Vaccination;Variant;Vertebral column

PROJECT_TITLE: Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia


PHR: NARRATIVE The majority of leukemia patients relapse after initial therapies, underscoring the need for improved targeted therapies and better predictors of clinical response. The Developmental Research Program supports innovative pilot projects, technologies and research collaborations that have the potential to improve the diagnosis, prevention, and/or treatment of leukemia.

PROJECT_TERMS: Basic Science;bench-to-bedside translation;Biological Markers;Blood;Clinical;clinical predictors;Clinical Sciences;Clinical Trials;Collaborations;Communities;community center;Community Physician;Computing Methodologies;Dedications;Development;Diagnosis;Disease Management;Doctor of Philosophy;Faculty;Funding;Goals;Grant;Hematologic Neoplasms;high reward;high risk;Home;Immunology;improved;Incubators;Individual;innovation;Institution;Investigation;leukemia;leukemia treatment;Malignant Neoplasms;medical schools;meetings;member;Memorial Sloan-Kettering Cancer Center;Molecular Genetics;Monitor;new technology;novel;novel strategies;Oncology;Pathogenesis;Patients;Peer Review;Pilot Projects;Policies;Prevention;Procedures;Program Research Project Grants;programs;Refractory;Relapse;relapse patients;Research;Research Personnel;Research Priority;Research Project Grants;Research Proposals;Research Support;response;Science;Scientist;Series;Talents;targeted treatment;Technology;therapy resistant;translational cancer research;Translational Research;Treatment Protocols;treatment response;Underrepresented Minority;Universities;Woman;Work;working group

PROJECT_TITLE: Developmental Research Program


PHR: PROJECT NARRATIVE The Career Enhancement Program (CEP) provides support to talented junior faculty, or established faculty who wish to attain additional training, who are conducting research related to the diagnosis, prevention, or treatment of leukemia.

PROJECT_TERMS: Address;Appointment;Area;Award;Basic Science;Biological Assay;Biomedical Research;Caliber;career;career development;Career Mobility;Cellular biology;chimeric antigen receptor;chimeric antigen receptor T cells;Clinical;clinical care;Clinical Research;Clinical Sciences;Clinical Trials;Collaborations;Communities;Computational Biology;computational platform;Data;Dedications;Development;Development Plans;Diagnosis;Environment;Ethnic Population;Evaluation;experience;Faculty;Fostering;Funding;Genetic;Health Care Research;Hematology;Immunology;improved;Individual;Institution;Investigational Therapies;Knowledge;leukemia;leukemia treatment;Medical Informatics;medical schools;member;Memorial Sloan-Kettering Cancer Center;Mentors;Minority;Modeling;Molecular Biology;Oncology;Pathogenesis;Pathology;patient derived xenograft model;Peer Review;Physicians;Postdoctoral Fellow;Prevention;programs;Qualifying;racial population;Receptor Cell;Recommendation;recruit;Research;research faculty;Research Infrastructure;Research Personnel;Research Proposals;Resources;Scientist;social;Talents;tool;Training;Translational Research;translational research program;Universities;Woman;Work;Writing

PROJECT_TITLE: Career Enhancement Program


NIH_SPENDING_CATS: Genetics;Infectious Diseases;Lyme Disease;Tickborne Diseases;Vector-Borne Diseases

ORG_CITY: LEXINGTON

ORG_DEPT: MICROBIOLOGY/IMMUN/VIROLOGY

ORG_NAME: UNIVERSITY OF KENTUCKY

ORG_STATE: KY

PHR: NARRATIVE The Lyme disease spirochete, Borrelia burgdorferi, produces a unique DNA-binding protein named Gac. Our biochemical and genetic analyses indicate that Gac regulates expression of several genes that encode proteins that are essential for mammalian infection, including the alternative sigma factors RpoN and RpoS. Our studies will define the role of Gac during B. burgdorferi infection processes, and assess the mechanism by which Gac controls transcription of RpoN.

PI_NAMEs: STEVENSON, BRIAN  (contact)

PROGRAM_OFFICER_NAME: BOWDEN, NADINE

PROJECT_TERMS: Anti-Bacterial Agents;Applications Grants;Bacteria;Bacteria sigma factor KatF protein;Bacterial Adhesins;Binding Sites;Biochemical;Borrelia;Borrelia burgdorferi;C-terminal;curative treatments;Development;DNA;DNA Binding Domain;DNA Gyrase;DNA-Binding Proteins;Enzymes;Exhibits;Genes;genetic analysis;improved;Infection;Initiator Codon;insight;Investigation;Life;Lyme Disease;Mammals;Membrane Proteins;Messenger RNA;Molecular;Mus;mutant;Names;novel;Open Reading Frames;Operon;OspC protein;pathogenic microbe;Process;Production;promoter;Protein Binding Domain;protein expression;Proteins;Regulation;Reporter;Ribosomes;Role;Series;Sigma Factor;Site;Structure;Surface;Tertiary Protein Structure;Ticks;Time;Transcript;Transcription Repressor;Transcriptional Regulation;transcriptome sequencing;transmission process;vector;Vertebrates;Virulence

PROJECT_TITLE: Impacts of Borrelia burgdorferi Gac protein on infectivity and regulation of virulence protein expression

STUDY_SECTION: TVZ

STUDY_SECTION_NAME: Transmission of Vector-Borne and Zoonotic Diseases Study Section [TVZ]


NIH_SPENDING_CATS: Biotechnology;Cancer;Digestive Diseases;Liver Cancer;Liver Disease;Orphan Drug;Precision Medicine;Rare Diseases

ORG_CITY: SEATTLE

ORG_NAME: UNIVERSITY OF WASHINGTON

ORG_STATE: WA

PHR: Public Health Relevance/Narrative  Precision medicine in oncology requires accurate prediction of drug response to guide personalized treatment decisions. We developed a pharmacoproteomics platform that links kinome activity in liver cancer cell lines to kinase inhibitor drug response; we will optimize our KI-Predictor in liver cancer and test its ability to select useful kinase inhibitor drugs in cell lines and organotypic slice culture models as a validation platform for predicting drug response in cancer. The combination of prediction and drug testing in a validation platform enhances the accuracy and translatability of the predictions, facilitating the advancement of precision medicine in oncology by aiding clinicians in selecting optimal treatment strategies tailored to individual patients.

PI_NAMEs: ONG, SHAO-EN  (contact);YEUNG, RAYMOND

PROGRAM_OFFICER_NAME: COVELL, DAVID G

PROJECT_TERMS: Animals;Antineoplastic Agents;biobank;Biological Assay;Biopsy Specimen;cancer cell;Cancer cell line;cancer initiation;cancer type;candidate selection;Cell Death;Cell Line;Cell Physiology;Cellular Assay;Cervical Adenocarcinoma;Classification;Clinical;clinical application;clinical implementation;companion diagnostics;Data;Data Set;design;dimension reduction;drug response prediction;Drug Screening;drug sensitivity;drug testing;Effectiveness;Epidermal Growth Factor Receptor;Etiology;Excision;Exposure to;Extracellular Matrix;Future;Gene set enrichment analysis;Genomics;Goals;Growth;Hela Cells;hepatocellular carcinoma cell line;Hepatocyte;Histology;Human;improved;Individual;individual patient;inhibitor;inhibitor therapy;kinase inhibitor;Learning;Link;Liver;Liver neoplasms;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant Neoplasms;Maps;Melanoma;Messenger RNA;Metabolic;Metabolism;Methods;Modeling;Molecular;Mutation;Nature;Needles;Oncologist;Oncology;Operative Surgical Procedures;optimal treatments;Pathway interactions;Patients;Performance;personalized medicine;Pharmaceutical Preparations;Pharmacogenomics;Phosphorylation;Phosphotransferases;Play;precision medicine;predictive modeling;predictive test;Primary carcinoma of the liver cells;Proliferating;protein expression;Proteins;Proteome;proteomic signature;Proteomics;PTEN gene;public health relevance;Publishing;rational design;Renal Cell Carcinoma;Reproducibility of Results;Resistance;response;rho;Role;Sampling;Signal Pathway;Signal Transduction;Slice;Specificity;Stress;Stromal Cells;Stromal Neoplasm;System;targeted treatment;Testing;Therapeutic Agents;Tissues;tool;transcriptomics;treatment strategy;tumor;tumor growth;tumor microenvironment;tumor progression;Tumor Tissue;tumorigenesis;Validation

PROJECT_TITLE: Proteomic signatures to predict drug response in cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-F (J2)]


ADMINISTERING_IC: HL

ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Behavioral and Social Science;Cardiovascular;Clinical Research;Clinical Trials and Supportive Activities;Digestive Diseases;Heart Disease;Liver Disease;Nutrition;Obesity;Physical Activity;Physical Rehabilitation;Prevention;Rehabilitation

ORG_CITY: MINNEAPOLIS

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: UNIVERSITY OF MINNESOTA

ORG_STATE: MN

PHR: PROJECT NARRATIVE Exercise-based prevention and treatment strategies for heart failure with preserved ejection fraction (HFpEF) have historically focused on the promotion of aerobic exercise. However, given the coinciding epidemics of physical inactivity and obesity in the U.S., and the compromised aerobic capacity and exercise intolerance in patients with HFpEF, long-term adherence to aerobic exercise is generally poor and thus, the prevention and treatment of HFpEF remains a major public health challenge. To help alleviate this public health burden, the proposed project will be the first to examine the isolated role of resistance exercise—a more movement-varied, non-weight-bearing exercise modality that may be better tolerated by obesity-burdened, aerobically- compromised populations—in the prevention and treatment of HFpEF, with examination of potential biological intermediates.

PI_NAMEs: MCDONOUGH, DJ  (contact)

PROGRAM_OFFICER_NAME: COADY, SEAN

PROJECT_TERMS: Activities of Daily Living;Adherence;Adipose tissue;adjudication;Aerobic;Aerobic Exercise;Affect;Applications Grants;arm;Bioenergetics;Biological;Biological Markers;Biomedical Research;biracial;Blood flow;Brain natriuretic peptide;Cardiac;cardiometabolism;career;Career Transition Award;Clinical;Clinical Trials;cohort;Cohort Studies;comorbidity;Data;Diagnosis;Diet;EFRAC;Epidemic;Epidemiologist;Epidemiology;Etiology;Event;Exercise;exercise adherence;exercise intervention;exercise intolerance;Exercise Therapy;exercise training;Exertion;Fatty acid glycerol esters;Functional disorder;Future;global health;Goals;Guidelines;Healthcare Systems;Heart failure;heart failure with reduced ejection fraction;Heavy Drinking;Hepatic;Heterogeneity;Hospitalization;Impairment;improved;Inflammatory;insight;Institution;interest;Intervention;Legal patent;Link;Liver;longitudinal analysis;Measures;Mediation;Mediator;Mentors;Mentorship;Meta-Analysis;Methods;middle age;Minnesota;mode of exercise;Modeling;mortality;Movement;N-terminal;National Heart, Lung, and Blood Institute;non-alcoholic fatty liver disease;novel;Obesity;Outcome;Overweight;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;Phase;Phenotype;Physical activity;physical inactivity;Physicians;Plasma;Population;Positioning Attribute;Postdoctoral Fellow;preservation;Prevalence;Prevention;Prevention strategy;primary outcome;Primary Prevention;programs;Public Health;Quality of life;randomized, clinical trials;Regression Analysis;Research;Research Personnel;Research Priority;Resistance;resistance exercise;Resources;Role;Science;Scientist;Secondary Prevention;Skeletal Muscle;skeletal muscle wasting;Statistical Data Interpretation;Statistical Models;Survival Analysis;targeted treatment;Therapeutic;Training;Translating;treatment strategy;treatment trial;Troponin T;United States National Institutes of Health;Universities;Viral hepatitis;Visceral fat;Visit;Weight;X-Ray Computed Tomography

PROJECT_TITLE: Resistance Exercise in the Prevention and Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

STUDY_SECTION_NAME: Special Emphasis Panel[ZHL1 CSR-L (J1)]


ADMINISTERING_IC: EB

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

ORG_CITY: BALTIMORE

ORG_DEPT: PATHOLOGY

ORG_NAME: JOHNS HOPKINS UNIVERSITY

ORG_STATE: MD

PHR: Narrative Our rapidly increasing understanding of the power of immune effectors, combined with development of advanced genomic tools, has generated the new field of immunoengineering, with a promise to revolutionize treatments for infectious disease, autoimmune disorders, and cancer. However, application of these breakthroughs has been stymied by remaining knowledge gaps, inefficiencies, and operational barriers between immunologists, engineers, and other partners who could collaborate and innovate. Our goal in this renewal is to continue interfacing with bioengineers, immunologists, material scientists, and biomedical researchers to develop tools, techniques, and protocols that are broadly relevant to immune and inflammatory diseases; engage in new collaborations; provide training for graduate and post-graduate investigators; and maximize the potential of immunoengineering and immune-based therapies.

PI_NAMEs: GREEN, JORDAN ;SCHNECK, JONATHAN P (contact)

PROGRAM_OFFICER_NAME: CHEN, JERMONT

PROJECT_TERMS: Acceleration;Address;Advanced Development;Advisory Committees;Antibodies;Antigen Presentation;Antigen-Presenting Cells;Antigens;Autoimmune Diseases;Autoimmunity;Biocompatible Materials;Biomedical Engineering;Capital;Cell Therapy;Cells;cellular engineering;cellular targeting;Chemical Engineering;Chimeric Proteins;Clinical;clinical application;Collaborations;Communicable Diseases;Communication;Communities;conflict resolution;Cues;cytokine;Dedications;Dendritic Cells;Dermatology;design;Development;Discipline;Disease;Education;Education and Outreach;Educational Curriculum;Educational workshop;effector T cell;Engineering;Event;Evolution;Foundations;Funding;General Population;genomic tools;Goals;Grant;hackathon;imaging agent;Immune;Immune response;Immune System Diseases;Immunity;immunoengineering;Immunologics;Immunologist;immunoregulation;Immunosuppression;Immunotherapy;in vivo;Industry;infectious disease treatment;Inflammatory;Infrastructure;innovation;Institution;interest;Jordan;Knowledge;leadership development;Macrophage;Malignant Neoplasms;materials science;metabolic profile;Methods;Microscopy;Modeling;Molecular;molecular imaging;multidisciplinary;nanobiotechnology;nanoscale;Nanotechnology;neoplasm immunotherapy;next generation;Nomenclature;novel;Oncology;Organ;Outcome;outreach;outreach program;pandemic disease;Pathology;Policy Maker;posters;precision medicine;programs;Proteins;Protocols documentation;Publications;Research;Research Personnel;Resources;Scientist;Seasons;Services;Signal Transduction;Students;symposium;System;T-Cell Activation;T-Lymphocyte;Techniques;Technology;technology research and development;Tissue Engineering;Tissues;tool;tool development;Training;Training Programs;Translations;Vision;web site;Work

PROJECT_TITLE: The Johns Hopkins Translational ImmunoEngineering (JH-TIE)

STUDY_SECTION_NAME: Special Emphasis Panel[ZEB1 OSR-D (J2)]


PI_NAMEs: SCHNECK, JONATHAN P (contact)

PROJECT_TERMS: Address;Administrator;Advisory Committees;Annual Reports;Area;Cellular immunotherapy;Collaborations;college;conflict resolution;Decision Making;Dedications;design;Education;Educational process of instructing;Engineering;Ensure;Equipment;Equity;experience;Fellowship;Funding;Grant;Guidelines;immunoengineering;Immunologist;innovation;Institution;Intellectual Property;Jordan;Lead;Leadership;Licensing;Maintenance;meetings;member;Mission;National Institute of Biomedical Imaging and Bioengineering;operation;organizational structure;Pathology;Persons;Play;Postdoctoral Fellow;Preparation;Procedures;programs;Progress Reports;Reporting;Research;Research Personnel;Resources;Role;Schedule;Services;Structure;symposium;synergism;Teacher Professional Development;Technology;Training;United States National Institutes of Health;virtual;web site;Writing


PROJECT_TERMS: Adoptive Transfer;Affinity;Antigen-Presenting Cells;antigen-specific T cells;Antigens;Artificial nanoparticles;Autoimmunity;Biological;biomaterial compatibility;Biomechanics;Biomimetic Materials;cancer immunotherapy;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;CD8B1 gene;Cell Surface Proteins;Cells;Clinical;combinatorial;cost;Coupling;Cues;cytokine;Cytoplasmic Granules;cytotoxic;cytotoxic CD8 T cells;Cytotoxic T-Lymphocytes;Data Set;density;Disease;engineered T cells;Engineering;Extracellular Matrix;Gene Expression Profile;Generations;Goals;Histocompatibility Antigens Class I;Histocompatibility Antigens Class II;HLA Antigens;Human;humanized mouse;Hyaluronic Acid;Hydrogels;IL27RA gene;Immune response;immunoengineering;Immunotherapeutic agent;Immunotherapy;improved;In Vitro;in vivo;innovation;interest;lymph nodes;Lytic;Malignant Neoplasms;Mechanics;Memory;Modeling;mouse model;Mus;nanoparticle;next generation;novel;Outcome;particle;Performance;Phenotype;process optimization;Production;prototype;Research Personnel;Signal Transduction;synergism;T cell therapy;T-Cell Activation;T-Lymphocyte;T-Lymphocyte Subsets;Technology;technology platform;Testing;therapy outcome;Time;Transcript;transcriptome sequencing;transcriptomics;tumor;Tumor Cell Line;vaccine development;Vaccines

PROJECT_TITLE: TR&D Project 1


PI_NAMEs: GREEN, JORDAN  (contact)

PROJECT_TERMS: Adjuvant;Amines;Antigen Targeting;Antigen-Presenting Cells;antigen-specific T cells;Antigens;Autoimmunity;Binding;Biocompatible Materials;Biodistribution;Biological;Biological Products;Biomedical Engineering;Cancer Model;Cancer Vaccines;Capsid Proteins;Cell Surface Proteins;Cells;Chemical Engineering;Chemical Structure;Chemicals;Chemistry;Communities;Custom;cytotoxic CD8 T cells;Dendritic Cells;design;DNA;Drug Kinetics;efficacy evaluation;engineered T cells;Engineering;Esters;Experimental Autoimmune Encephalomyelitis;Flow Cytometry;Formulation;Gene Delivery;Genetic Engineering;genetic manipulation;Genetic Programming;genetic vaccine;Goals;Health;Human;Hydrophobicity;Immune;Immune Targeting;Immunity;immunoengineering;Immunology;immunoregulation;Immunotherapy;improved;In Situ;In Vitro;in vivo;Injections;Kinetics;Libraries;Ligands;Lipids;lipophilicity;Lymphoma;Macrophage;Maps;materials science;Melanoma;Messenger RNA;Modeling;Multiple Sclerosis;Mus;nanocarrier;nanomaterials;nanoparticle;nanopolymer;novel vaccines;nucleic acid delivery;Nucleic Acids;Oncology;particle;Particle Size;physical property;Polymers;Production;programs;Property;Protein Engineering;Reagent;Reporter;Research;Research Personnel;Role;Safety;Specificity;Spleen;Structure;Surface;surface coating;synergism;System;T-Lymphocyte;targeted delivery;targeted treatment;Technology;Testing;Therapeutic;Tissues;tool;Toxic effect;Transfection;Tumor Antigens;uptake;vaccine efficacy;Vision

PROJECT_TITLE: TR&D Project 2


NIH_SPENDING_CATS: Autoimmune Disease;Bioengineering;Biotechnology;Cancer;Digestive Diseases;Gene Therapy;Genetics;Immunotherapy;Inflammatory Bowel Disease

PI_NAMEs: SPANGLER, JAMIE BERTA (contact)

PROJECT_TERMS: Adoption;Animal Cancer Model;Animal Model;antagonist;anti-cancer;Antibodies;Antigen-Presenting Cells;Antigens;Autoimmune Diseases;Award;Binding;Biomedical Engineering;Biophysics;cancer immunotherapy;cancer therapy;Categories;Cell model;Cell Survival;Cells;Cellular biology;Chimeric Proteins;Circulation;Clinical;clinical translation;Colorectal Cancer;Communicable Diseases;cytokine;cytokine therapy;design;Development;Disease;disorder control;Dominant-Negative Mutation;Effector Cell;empowerment;Engineering;FDA approved;Formulation;Gene Delivery;Glucocorticoids;Goals;Half-Life;Homeostasis;Human;IL7 gene;Immune;immune activation;Immune checkpoint inhibitor;Immune response;immunoengineering;Immunoglobulin Fragments;Immunologic Stimulation;Immunologist;immunoregulation;Immunosuppression;Immunotherapy;improved;in vivo;Infiltration;Inflammatory Bowel Diseases;Insulin-Dependent Diabetes Mellitus;interest;Interleukin-2;Intervention;Link;link protein;Malignant Neoplasms;manufacturability;Mediating;Melanoma;Molecular;mouse model;novel;Outcome;OX40;Pathway interactions;Patients;Performance;Pharmaceutical Preparations;Phenotype;pleiotropism;Population;preclinical study;Proliferating;Property;Protein Engineering;Proteins;Regulatory T-Lymphocyte;Resistance;response;Safety;Services;Signal Transduction;Signaling Protein;single molecule;Site;Specificity;success;synergism;System;T-Lymphocyte;targeted treatment;Technology;Therapeutic;therapeutic evaluation;Therapeutic Index;tool;Transplantation Tolerance;Treatment Efficacy;treatment response;tumor;Tumor Immunity;tumor microenvironment;Tumor Necrosis Factor Receptor;tumor necrosis factor receptor superfamily member 4;Ulcerative Colitis;Validation;Work

PROJECT_TITLE: TR&D Project 3


PI_NAMEs: SUNSHINE, JOEL CHAIM (contact)

PROJECT_TITLE: Tech-Train-Dissem Core


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Patient Safety;Precision Medicine;Racial and Ethnic Minority Health Research;Social Determinants of Health

ORG_CITY: KANSAS CITY

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF KANSAS MEDICAL CENTER

ORG_STATE: KS

PHR: Project Narrative In this project, Dr. Baranda will continue to lead in the development of sustainable and intentional strategies to extend access and increase participation to early phase Experimental Therapeutics Clinical Trials Network (ETCTN) clinical trials to underrepresented populations including the veterans using a roadmap built from lessons learned from the National Cancer Institute’s (NCI) CATCH-UP.2020 (Create Access to Targeted Cancer Therapy for Underserved Populations) program.

PI_NAMEs: BARANDA, JOAQUINA C (contact)

PROGRAM_OFFICER_NAME: TAWAB-AMIRI, ABDUL

PROJECT_TERMS: Achievement;Adopted;Area;Area Analyses;biomarker driven;Cancer Biology;cancer care;cancer health disparity;cancer therapy;Catchment Area;Clinical Investigator;Clinical Trials;Clinical Trials Design;Clinical Trials Network;Complex;Development;early phase clinical trial;early phase trial;effective therapy;Ensure;Equity;Genomics;health care availability;improved;Investigational Therapies;Lead;Medical;metropolitan;Minority;minority engagement;National Cancer Institute;novel;novel strategies;novel therapeutics;operation;Outcome;Patients;Phase;Physicians;Population;precision medicine clinical trials;prevent;programs;psychologic;Quality of life;Risk;Site;Societies;Sustainable Development;targeted cancer therapy;tumor;Underrepresented Populations;Underserved Population;Veterans

PROJECT_TITLE: Increasing Access and Participation to Early Phase Clinical Trials to the Underrepresented Populations

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-1 (J1)]


ORG_CITY: SAINT LOUIS

ORG_NAME: WASHINGTON UNIVERSITY

ORG_STATE: MO

PHR: Project Narrative. Our ReVAMMP Center (Flavivirus and Alphavirus ReVAMPP, FLARE) addresses the hypothesis that innovative approaches to antigen and vaccine design and monoclonal antibody screening will promote the development of platform technologies that can rapidly generate countermeasures against current and future flavivirus and alphavirus threats. With our allied industry partners, we will develop and optimize protein nanoparticle, virion- based, and mRNA vaccines, and mAb-based treatments to respond to emerging flaviviruses and alphaviruses with pandemic potential using a pathogen prototype, modular approach.

PI_NAMEs: DIAMOND, MICHAEL S (contact);KUHN, RICHARD J.

PROGRAM_OFFICER_NAME: BRIDWELL, ANNE ELIZABETH MAYER

PROJECT_TERMS: Address;Ally;Alpha Virus;Animal Disease Models;Animal Model;Animals;Antibodies;Antibody Therapy;Antibody-mediated protection;Antigens;Arthritogenic;Artificial Intelligence;B-Lymphocytes;Back;Binding;Biological Assay;Biological Products;Biology;biophysical analysis;Characteristics;Chikungunya virus;clinical efficacy;Collaborations;combat;Combined Modality Therapy;computer studies;Data;data dissemination;data management;Dengue Virus;design;Development;Disease;Distant;emerging virus;Encapsulated;env Gene Products;Epidemic;Epitopes;Evaluation;experience;experimental study;Family;Flavivirus;Future;future outbreak;Gene Modified;Generations;Goals;Half-Life;human monoclonal antibodies;Immune;Immunity;immunogenicity;Immunologics;Immunology procedure;industry partner;Infection;innovation;Insect Viruses;iterative design;Knowledge;Life Cycle Stages;Lipids;mathematical model;Membrane Fusion;Messenger RNA;Monoclonal Antibodies;Monoclonal Antibody Therapy;Mus;nanoparticle;new pandemic;nonhuman primate;Output;pandemic disease;pandemic potential;pathogen;Pathogenesis;Phase;Play;Process;Protein Engineering;protein structure;Protein Subunits;Proteins;prototype;Records;Regression Analysis;Research Personnel;Research Project Grants;Resistance;response;RNA vaccine;Safety;screening;structural biology;Structural Protein;Structure;synergism;T cell response;T-Lymphocyte;technology platform;Testing;Therapeutic Monoclonal Antibodies;Tick-Borne Encephalitis Virus;Translating;Vaccination;Vaccine Design;vaccine development;vaccine platform;Vaccine Therapy;vaccine trial;vaccine-induced antibodies;Vaccines;vaccinology;vector;Venezuelan Equine Encephalitis Virus;Venezuelan Equine Encephalomyelitis;Viral;Virion;Virus;West Nile virus;Work

PROJECT_TITLE: Flavivirus and Alphavirus ReVAMPP (FLARE)

STUDY_SECTION_NAME: Special Emphasis Panel[ZAI1 SJ-M (J1)]


PI_NAMEs: DIAMOND, MICHAEL S (contact)

PROJECT_TERMS: Accountability;Alpha Virus;Budgets;Career Mobility;Collaborations;collaborative environment;Communication;conflict resolution;Data;data management;data sharing;Development;Documentation;Ensure;Faculty;Financial Support;Flavivirus;Focus Groups;Goals;Grant;implementation measures;Individual;industry partner;Institution;Logistics;Manuscripts;marginalized population;Measures;meetings;member;Mentors;Mission;National Institute of Allergy and Infectious Disease;next generation;pandemic preparedness;Preparation;programs;Progress Reports;Publications;Reporting;Research;Research Activity;Research Personnel;Resource Allocation;Science;Services;Structure;symposium;Travel;Underrepresented Populations;United States National Institutes of Health;virtual;Woman;Work

PROJECT_TITLE: Core A: Administrative


PI_NAMEs: GOSS, CHARLES  (contact)

PROJECT_TERMS: access restrictions;Address;Alpha Virus;Antigens;application programming interface;cloud based;cloud storage;Collaborations;collaborative environment;Common Data Element;Communities;Computer software;Data;data cleaning;data exchange;data harmonization;data interoperability;data management;Data Management Resources;data modeling;data platform;Data Provenance;data repository;data reuse;data sharing;data standards;data visualization;design;Development;educational atmosphere;electronic data;Electronic Mail;Ensure;FAIR principles;Flavivirus;Fostering;Genbank;Goals;Health;improved;Informatics;Information Dissemination;Interdisciplinary Study;Licensing;Link;Metadata;Monoclonal Antibody Therapy;novel;Outcome;Play;prospective;Publications;Quality Control;Reporting;repository;Research;Research Personnel;research study;Resources;Role;Standardization;Statistical Data Interpretation;System;Systems Analysis;Time;vaccine platform;Work

PROJECT_TITLE: Core B:  Data Management


PI_NAMEs: KUHN, RICHARD J. (contact)

PROJECT_TERMS: Affect;Alpha Virus;Amino Acid Substitution;Antibodies;Antibody Affinity;Antibody Binding Sites;antibody engineering;Antigen Targeting;Antigen-Antibody Complex;Antigenic Diversity;Antigens;biophysical analysis;biophysical techniques;Biophysics;Calorimetry;Cell Culture Techniques;Chikungunya virus;Collaborations;Complex;Computational Biology;Computer Models;Containment;Cryoelectron Microscopy;Data;data exchange;data sharing;design;Development;Disease;Engineering;Ensure;env Gene Products;Epidemic;Epitopes;Evaluation;experience;Flavivirus;Goals;High Performance Computing;human disease;Immune response;Immunity;in vivo;insight;Interferometry;Kinetics;Laboratories;Ligands;Machine Learning;machine learning method;Maps;member;Methods;Molecular;Molecular Evolution;Monoclonal Antibodies;Mutation;mutation screening;nanoparticle;neutralizing monoclonal antibodies;novel;pandemic potential;particle;Pharmaceutical Preparations;Phylogenetic Analysis;Play;polyclonal antibody;prediction algorithm;Production;Protein Analysis;Protein Engineering;Proteins;prototype;Reagent;receptor;Research;RNA Viruses;scaffold;self assembly;Series;Serum;Shapes;simulation;Site;Specificity;structural biology;structural determinants;Structure;Surface Plasmon Resonance;Technology;Testing;Therapeutic antibodies;Thermodynamics;Time;Titrations;Trees;vaccine candidate;Vaccine Design;Vaccines;Viral Envelope Proteins;Viral Proteins;Virion;Virus;Virus-like particle;Work;X-Ray Crystallography

PROJECT_TITLE: Core C: Structure, Computational, Protein Engineering


PI_NAMEs: STREBLOW, DANIEL N (contact)

PROJECT_TERMS: Alpha Virus;animal care;Animal Model;animal model development;Animals;Antigens;arthropod-borne;Autopsy;Back;biocontainment facility;Biological Assay;Biometry;Blood;chikungunya;Chikungunya virus;Data;Dengue;Dengue Virus;design;Development;Diamond;Disease;dosage;Dose;efficacy study;efficacy testing;Epidemic;experience;Experimental Designs;experimental study;Flavivirus;Formulation;Future;global health;Goals;Histologic;Human;Immune response;immunogenicity;Lead;Licensing;Life;Location;Mayaro virus;member;model development;Modeling;Monoclonal Antibodies;mouse model;Mus;nasal swab;nonhuman primate;pandemic potential;Pathogenicity;Persons;Play;pre-clinical;Pre-Clinical Model;Procedures;Process;prototype;Readiness;Research;Research Personnel;Safety;safety assessment;sample collection;Sampling;Shipping;Standardization;Technology;Testing;Therapeutic;Therapeutic antibodies;therapeutic evaluation;Therapeutic Monoclonal Antibodies;Tick-Borne Encephalitis Virus;tissue processing;Travel;Urine;Vaccination;vaccine access;vaccine candidate;vaccine evaluation;vaccine-induced antibodies;Vaccines;vector mosquito;Venezuelan Equine Encephalitis Virus;Viral Pathogenesis;Virus;Virus Diseases;West Nile;West Nile virus;Western Equine Encephalitis Virus

PROJECT_TITLE: Core D: Animal Immunogenicity and Challenge


PROJECT_TERMS: abortion;Acute;Affect;Alpha Virus;Animal Model;Animals;Anti-viral Therapy;Antibodies;Antibody-mediated protection;Antigens;Arboviruses;Archives;arthropod-borne;Benchmarking;Binding;Biological Assay;Case Fatality Rates;Cessation of life;Characteristics;Chikungunya virus;Child;Chronic;Clinical;Cohort Studies;congenital anomaly;Data;Data Analyses;Data Protection;Dengue Fever;Dengue Infection;Dengue Vaccine;Dengue Virus;Dengvaxia;design;Developed Countries;Development;Diamond;Disease;Encephalitis;Epidemic;Epitope Mapping;Family;Family member;Feedback;Flaviviridae;Flavivirus;Future;Goals;Health Benefit;Human;human data;human disease;Immune;Immunity;immunogenicity;Immunoglobulin G;Immunology procedure;improved;Individual;Infection;Japanese encephalitis virus;Licensing;Link;member;Microcephaly;Mission;Modeling;Monoclonal Antibodies;Multivariate Analysis;Mus;Neurologic;neutralizing monoclonal antibodies;novel;O'nyong'nyong;Output;pandemic potential;Pathogenicity;Persons;Play;Polyarthritides;prototype;Public Health;Regression Analysis;Research;Research Personnel;Research Project Grants;RNA Viruses;Safety;Sampling;Serotyping;Serum;severe dengue;Severities;Specimen;Survivors;T cell response;Technology;Testing;Therapeutic antibodies;tick-borne flavivirus;Togaviridae;Transgenic Mice;Vaccinated;vaccine evaluation;vaccine immunogenicity;vaccine platform;vaccine response;vaccine safety;vaccine trial;vaccine-induced antibodies;Vaccines;vaccinology;Venezuelan;Venezuelan Equine Encephalitis Virus;Viral;Virus;West Nile virus;Western Equine Encephalitis Virus;Zika Virus;Zoonoses

PROJECT_TITLE: Core E: Correlates of Protection


PI_NAMEs: SCHMIDT, AARON GREGORY (contact)

PROJECT_TERMS: Alpha Virus;Animals;Antibodies;Antigens;Architecture;Arthropod Vectors;B-Cell Antigen Receptor;B-Lymphocytes;Cell surface;Cells;Central Nervous System;Complex;Computing Methodologies;crosslink;Cryoelectron Microscopy;Culicidae;Cysteine;design;Diffusion;dimer;Directed Molecular Evolution;Disulfides;Dose;E protein;Electron Microscopy;Encephalitis;Engineering;Ensure;epidemic potential;Epitope Mapping;Epitopes;Evaluation;Ferritin;Flavivirus;Flavivirus Infections;Future;Glycoproteins;glycosylation;Health;Human;Huntingtin-Associated protein 1;Immune;Immune response;immunogenicity;improved;in vivo;in vivo evaluation;industry partner;Infection;Injury;iterative design;light scattering;Link;lumazine;Mammalian Cell;Maps;Membrane;Messenger RNA;Modeling;Modification;Molecular;Molecular Conformation;Monoclonal Antibodies;Morbidity - disease rate;mortality;mouse model;Mus;nanoparticle;Negative Staining;Neurons;neurotropic;non-Native;nonhuman primate;novel;novel vaccines;pandemic potential;particle;pathogen;Play;Polysaccharides;Powassan virus;Protein Engineering;Proteins;prototype;response;scaffold;Serum;Site;Structure;Surface;Testing;Tick-Borne Encephalitis Virus;Ticks;Tropism;vaccine candidate;Vaccine Design;vaccine efficacy;vaccine platform;vaccine strategy;Vaccines;Viral Hemorrhagic Fevers;viral transmission;Virion;Virus;West Nile virus;Work;X-Ray Crystallography;Yeasts;Zika Virus

PROJECT_TITLE: Project 1: Vaccine Design Neurotropic Flaviviruses


PI_NAMEs: DESILVA, ARAVINDA M. (contact)

PROJECT_TERMS: Address;Agreement;Alpha Virus;Animal Model;Animals;Antibodies;Antigens;Architecture;Archives;Area;Arthropod Vectors;Binding;Blood specimen;Chimeric Proteins;Clinical Trials;Collaborations;Complex;Country;cross reactivity;Data Protection;Dengue Infection;Dengue Vaccine;Dengue Virus;design;Development;dimer;Distant;E protein;Ecology;Encapsulated;env Gene Products;Epidemic;Epidemiology;Epitopes;Evaluation;Exposure to;Flavivirus;flavivirus glycoprotein E;Future;future epidemic;Goals;Health;Higher Order Chromatin Structure;Human;human monoclonal antibodies;Immune response;Immunity;Immunize;immunogenicity;Immunology procedure;improved;industry partner;Infection;Lead;Link;Lipids;Maps;member;Messenger RNA;Methods;Minor;Modeling;monomer;Mus;Mutation;nanoparticle;neutralizing antibody;neutralizing monoclonal antibodies;nonhuman primate;North Carolina;novel;Pathogenicity;Performance;Persons;Play;Protein Engineering;protein structure;Protein Subunits;Proteins;prototype;Recombinant Proteins;Recombinants;response;RNA vaccine;scaffold;screening;Secondary to;self assembly;Serotyping;Structure;Subunit Vaccines;Surface;T cell response;Technology;technology platform;Testing;Therapeutic Monoclonal Antibodies;Tick-Borne Encephalitis Virus;transmission process;Universities;Vaccination;vaccination strategy;Vaccine Antigen;vaccine candidate;vaccine delivery;Vaccine Design;vaccine development;vaccine platform;Vaccines;Variant;vector;vector-borne;Viral;Virion;Virus;Virus Assembly;virus testing;West Nile;Zika Virus

PROJECT_TITLE: Project 2: Vaccine Design Epidemic Flaviviruses


PI_NAMEs: LAI, JONATHAN R. (contact)

PROJECT_TERMS: Aedes;Alpha Virus;Americas;Animals;Antigens;Arthralgia;Arthritis;Arthritogenic;Attenuated;Binding;Brain;Brazil;Cell surface;Cell-Matrix Junction;Cells;Central America;Characteristics;chikungunya infection;Chikungunya virus;Clinical Trials;Collaborations;Complement 1q;Complex;Country;Coupled;Culicidae;design;Development;dimer;Disease;Disease Outbreaks;Encapsulated;Encephalitis;endosome membrane;Engineering;Epidemic;epidemic potential;Epitopes;epizootic;Evaluation;Fever;Flavivirus;Glycoproteins;Goals;Head;head-to-head comparison;Human;Immune response;immunogenic;immunogenicity;improved;in vivo;industry partner;Infection;Laboratory Personnel;Link;Lipids;Mediating;Membrane;Messenger RNA;Military Personnel;Molecular Conformation;Monoclonal Antibodies;mouse model;Mus;Musculoskeletal Diseases;nanoparticle;Nervous System Trauma;next generation;nonhuman primate;novel;novel strategies;novel vaccines;pandemic potential;Paraguay;particle;pathogen;Play;Population;Protein Engineering;Proteins;prototype;Public Health;receptor;response;Risk;RNA vaccine;Safety;South America;Structure;Surface;Syndrome;synergism;T-Lymphocyte Epitopes;Testing;transmission process;vaccine candidate;Vaccine Design;vaccine immunogenicity;vaccine platform;Vaccines;vector;vector mosquito;Venezuelan Equine Encephalitis Virus;Viral;viral transmission;Virus;Virus Diseases;Virus-like particle;Work

PROJECT_TITLE: Project 3: Vaccine Design [mRNA] VEEV/CHIKV (alphaviruses)


PI_NAMEs: WEAVER, SCOTT C (contact)

PROJECT_TERMS: Address;Adenoviruses;Alpha Virus;Antibody Response;Antibody titer measurement;Antigens;Arthritogenic;Attenuated Vaccines;B-Lymphocytes;Binding;Biological Assay;candidate identification;Cells;Chikungunya virus;Chimera organism;clinical development;Clinical Trials;Combined Vaccines;Complex;cross immunity;Development;Disease;Disease Outbreaks;DNA Vaccines;Dose;Early identification;Eastern Equine Encephalitis Virus;Eastern Equine Encephalomyelitis;efficacy evaluation;efficacy testing;Electroporation;emerging virus;Enzyme-Linked Immunosorbent Assay;Epidemic;experimental study;Fine needle aspiration biopsy;Flavivirus;Formulation;Future;future outbreak;Genetic;global health;Goals;Helper-Inducer T-Lymphocyte;Human;Immune;Immunity;Immunization;immunogenic;immunogenicity;Immunoglobulin G;Infection;Insecta;Insecticide Resistance;Investigational Drugs;Lead;lymph nodes;Macaca fascicularis;Measles;Measures;Memory B-Lymphocyte;Methods;microbial;Modeling;Morbidity - disease rate;Mus;nanoparticle;neutralizing antibody;nonhuman primate;novel strategies;novel vaccines;outbreak control;pandemic disease;pathogen;Pathogenesis;Persons;Phase;Phase I Clinical Trials;Plasma Cells;Polyproteins;Population;Preclinical Testing;Production;protective efficacy;Protocols documentation;prototype;Recommendation;Regimen;Research;response;RNA vaccine;Rodent;Route;Safety;safety testing;seroconversion;Serum;Specificity;Structure of germinal center of lymph node;T cell response;Testing;thermostability;Time;transmission process;Vaccination;vaccine candidate;vaccine delivery;Vaccine Design;vaccine development;vaccine platform;Vaccines;vector;vector competence;vector mosquito;Venezuelan Equine Encephalitis Virus;Vertebral column;Vertebrates;Virus;Virus-like particle;volunteer;Western Equine Encephalitis Virus

PROJECT_TITLE: Project 4: Vaccine Design [insect alphavirus chimera] VEEV/CHIKV (alphaviruses)


PI_NAMEs: CROWE, JAMES E (contact)

PROJECT_TERMS: Acute;Alpha Virus;Animals;Antibodies;Antibody Binding Sites;Antibody Repertoire;Antibody-mediated protection;Antigens;Binding;Biological Assay;chikungunya infection;Chikungunya virus;Chronic;Collaborations;combinatorial;Combined Modality Therapy;Computational algorithm;Computing Methodologies;cross reactivity;Cryoelectron Microscopy;Dengue Infection;Dengue Virus;design;Development;Dose;Encephalitis;Endowment;env Gene Products;Epidemic;Epitope Mapping;Epitopes;Exhibits;experimental study;Flavivirus;functional improvement;Gene Modified;genetic resistance;Geography;Half-Life;Hepatitis;Human;human monoclonal antibodies;Immune;improved;In Vitro;in vivo;Individual;Infection;innovation;Insecta;Lead;Mayaro virus;Mediating;Modeling;Monoclonal Antibodies;Mus;Musculoskeletal Diseases;Mutation;neutralizing antibody;neutralizing monoclonal antibodies;nonhuman primate;novel;pandemic potential;pathogen;Play;Population Density;pressure;prevent;Property;protective efficacy;Protein Engineering;prototype;receptor;Resistance;Resolution;response;RNA Viruses;screening;Serotyping;Specificity;Structure;Syndrome;synergism;Testing;tool;Transgenic Mice;transmission process;Treatment Efficacy;Urbanization;Vaccines;vaccinology;Variant;vector;Viral;Viral Hemorrhagic Fevers;Viral Physiology;Virus Diseases;West Nile virus

PROJECT_TITLE: Project 5: mAb Development Flaviviruses and Alphaviruses


FUNDING_MECHANISM: TRAINING, INDIVIDUAL

ORG_NAME: BOSTON CHILDREN'S HOSPITAL

PHR: PROJECT NARRATIVE Pediatric hydrocephalus is a life-threatening condition that is primarily caused by in-utero and perinatal infections and intraventricular hemorrhage. The underlying molecular pathology of how neuroinflammation from infection or hemorrhage during critical developmental periods leads to hydrocephalus is poorly understood. This proposal implements single-cell transcriptomics combined with core methods for studying the choroid plexus (ChP) to uncover the role that the ChP has in mediating neuroinflammation that can be leveraged for diagnostics and therapeutics to prevent the progression of inflammatory-driven hydrocephalus.

PI_NAMEs: HEHNLY, CHRISTINE ANNA (contact)

PROGRAM_OFFICER_NAME: KIM, JENNY LILY

PROJECT_TERMS: Address;Adult;Age;Apical;Biology;Blood;Boston;Brain;Case Study;Cell Physiology;Cells;Cerebral Ventricles;Cerebrospinal Fluid;Childhood;Choroid Plexus Epithelium;Colony-Stimulating Factor Gene;Colony-Stimulating Factors;Communicable Diseases;critical developmental period;critical period;CSF1R gene;Data;Development;Diagnostic;differential expression;Embryo;Epithelial Cells;Epithelium;Etiology;experimental study;Fellowship;Fluid Balance;Foundations;Gene Expression;gene therapy;genetic manipulation;Genetic Transcription;Goals;Hemorrhage;Heterogeneity;Histology;Homeostasis;Human;Hydrocephalus;Imaging Techniques;immune activation;in utero;in vivo;Infant;Infection;Inflammation;Inflammatory;Inflammatory Response;innovation;Intervention;Intraventricular;intraventricular hemorrhage;Knock-out;Laboratories;Life;Lipopolysaccharides;Macrophage;Macrophage Colony-Stimulating Factor;Macrophage Colony-Stimulating Factor Receptor;Mediating;Methods;Microglia;Modeling;Molecular;molecular pathology;mouse model;Mus;neuroinflammation;Neurologic;neurosurgery;Pathologic;Pediatric Hospitals;Perinatal Infection;Physicians;Population;Population Heterogeneity;premature;Preparation;prevent;Prevention;professor;programs;Publishing;receptor;Research Proposals;Resources;Rodent Model;Role;Side;Signal Transduction;single-cell RNA sequencing;Site;Source;Stains;Structure of choroid plexus;Study models;Techniques;tenure track;Testing;Therapeutic;therapeutic target;tissue preparation;tissue repair;Tissue Survival;TLR4 gene;tool;Training;transcriptomics;Ventricular;Work

PROJECT_TITLE: Leveraging Choroid Plexus M-CSF Signaling to Prevent Inflammatory-Driven Hydrocephalus

STUDY_SECTION: NST

STUDY_SECTION_NAME: NST-4 Study Section [NST-4]


ADMINISTERING_IC: VA

IC_NAME: Veterans Affairs

ORG_CITY: MADISON

ORG_NAME: WM S. MIDDLETON MEMORIAL VETERANS HOSP

ORG_STATE: WI

PHR: Effective healthcare-associated infection (HAI) prevention requires multiple complex interventions across the work system. The COVID-19 pandemic also broadly impacted HAI prevention, and increases in some HAI rates have been observed during the pandemic. There is now an urgent need to assess how the implementation of HAI prevention practices was impacted in order to 1) develop strategies to support the resumption of effective practices and 2) identify practices needing future analysis to develop implementation strategies that will maximize effectiveness while minimizing provider burden. In this pilot project, we will analyze the effects of the COVID-19 pandemic on HAI prevention through all work system elements (people, tasks, tools, environment, and organization). This analysis will identify practices interrupted during the pandemic with barriers and facilitators to resuming these practices. We will also use these findings to create a model for future, larger-scale implementation studies into HAI prevention during resource-constrained settings.

PI_NAMEs: KEATING, JULIE A (contact)

PROJECT_TERMS: Acute;acute care;Address;Area;Bathing;burnout;Catalogs;Clostridium difficile;Complex;COVID-19;COVID-19 impact;COVID-19 pandemic;COVID-19 pandemic effects;Data;Development;Devices;Disease Outbreaks;Effectiveness;Elements;Engineering;Environment;Equipment;Event;evidence base;Future;Goals;Guidelines;Hand;Health care facility;Health Personnel;Health Priorities;Healthcare;Healthcare Systems;healthcare-associated infections;Hospitals;Hygiene;implementation barriers;implementation evaluation;implementation strategy;implementation study;improved;Individual;Infection;Infection Control;Infection prevention;infection rate;information gathering;innovation;inpatient service;Inpatients;Interruption;Intervention;Interview;Logic;Maintenance;Measures;Medical center;Mental Health;Methodology;Modeling;multi-drug resistant pathogen;Nursing Staff;Oral;Outcome;pandemic disease;pandemic impact;pathogen;Patient Care;patient safety;Patients;Patterns of Care;personal protective equipment;Persons;Phase;Pilot Projects;pre-pandemic;prevent;prevention practice;Prevention strategy;Procedures;Process;Protocols documentation;Provider;Quality of Care;Reporting;Research Priority;Research Project Grants;Resource-limited setting;Resources;response;Risk Reduction;Route;Safety;Sepsis;Shock;Structure;supply chain;System;Systems Analysis;Technology;Testing;tool;Training;transmission process;trend;United States Department of Veterans Affairs;Ventilator;Veterans;Work

PROJECT_TITLE: Systems Analysis of Healthcare-Associated Infection Prevention during the COVID-19 Pandemic

STUDY_SECTION_NAME: HSR-5 Health Care System Organization and Delivery and Women's Health[HSR5]


ORG_CITY: CHARLESTON

ORG_NAME: RALPH H JOHNSON VA MEDICAL CENTER

ORG_STATE: SC

PHR: Lung cancer is responsible for more death in the United States than breast, prostate and colon cancer combined and is the number one cancer killer in veterans. This is because lung cancer is usually diagnosed when the disease has spread and cure is less likely. Screening for lung cancer with a scan finds cancer at an earlier stage when it is curable. Screening for lung cancer is recommended for people that are at high risk based on age and smoking history every year. Unfortunately, many people eligible for screening have not been screened and one reason is the distance needed to travel to a place offering it. The proposed study will evaluate the implementation of mobile lung cancer screening to understand facilitators and barriers and determine the impact of mobile lung cancer screening on offering, uptake and return for annual lung cancer screening.

PI_NAMEs: TANNER, NICHOLE TRIPICIAN (contact)

PROJECT_TERMS: Address;Adherence;Age;aged;Alabama;Ambulatory Care Facilities;Cancer Death Rates;Cessation of life;Classification;Clinical;cohort;Colon Carcinoma;Communities;Community Healthcare;cost;cost comparison;Data;data warehouse;Decision Making;Development;Diagnosis;Disease;Disparity;Early Diagnosis;economic impact;Eligibility Determination;Enrollment;Ensure;Evaluation;follow-up;formative assessment;Funding;Future;Goals;Health;high risk;high risk population;implementation cost;implementation evaluation;implementation facilitation;implementation facilitators;implementation outcomes;improved;innovation;insight;Interview;Location;low dose computed tomography;Lung;lung cancer screening;Maintenance;Malignant Breast Neoplasm;Malignant neoplasm of lung;Malignant neoplasm of prostate;Malignant Neoplasms;member;Methodology;Methods;Monitor;mortality;Oncology;oncology program;Outcome;Parkin;Patient-Focused Outcomes;Perception;Persons;Practical Robust Implementation and Sustainability Model;precision oncology;programs;Provider;Radiology Specialty;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recommendation;Research;Resources;response;Rural;satisfaction;Scanning;screening;screening program;screening services;Services;Site;Smoking History;South Carolina;success;Surveys;Technology;Time;traditional care;Travel;United States;uptake;Veterans;Veterans Health Administration;Work

PROJECT_TITLE: MOASIC: Mobile lung Screening evaluation and outComes


ED_INST_TYPE: HOSPITALS

NIH_SPENDING_CATS: Biotechnology;Cancer;Digestive Diseases;Genetics;Immunotherapy;Orphan Drug;Pancreatic Cancer;Precision Medicine;Rare Diseases

ORG_CITY: HOUSTON

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

PHR: Narrative The development of resistance to mutant KRAS inhibitors is currently a major obstacle for the treatment of KRAS mutant cancers and the underlying mechanisms are not well-understood. The proposed research is relevant to public health because it will reveal a newly-identified mechanism that contributes to the efficacy of KRAS- targeted therapy, and success of this proposal will not only expand our knowledge of KRAS signaling and biology but also shed light on novel therapeutic strategies against KRAS mutated cancer to achieve durable therapeutic response.

PI_NAMEs: YAO, WANTONG  (contact)

PROGRAM_OFFICER_NAME: CHEN, WEIWEI

PROJECT_TERMS: Affect;Affinity;anti-PD1 antibodies;Antibodies;antitumor effect;Area;Automobile Driving;Autophagocytosis;Bacterial Artificial Chromosomes;Biological Assay;Biology;Bypass;cancer therapy;Cell Death;cell growth;Cell Survival;Cells;Cellular Immunity;checkpoint therapy;Clinical;clinical development;Clinical Trials;Colorectal Cancer;Data;Dependence;Development;Disease;Ectopic Expression;efficacy evaluation;Exons;Food;General Population;Genes;Genetic;Genetically Engineered Mouse;Goals;Growth;Human;immune checkpoint blockade;improved;improved outcome;Individual;inhibition of autophagy;inhibitor;innovation;Integral Membrane Protein;Knowledge;KRAS oncogenesis;KRAS2 gene;KRASG12D;Maintenance;Malignant neoplasm of lung;Malignant neoplasm of pancreas;Malignant Neoplasms;Mediating;Mediator;Membrane;Membrane Proteins;Metabolic;Metabolism;Methodology;Modeling;Monoclonal Antibodies;mouse model;Mus;mutant;Mutate;Mutation;neoplastic cell;new therapeutic target;novel;novel strategies;novel therapeutic intervention;novel therapeutics;Nutrient;Oncogenic;Outcome;pancreatic cancer cells;pancreatic cancer model;pancreatic cancer patients;Pancreatic Ductal Adenocarcinoma;pancreatic ductal adenocarcinoma cell;pancreatic ductal adenocarcinoma model;Pathway interactions;Patient-Focused Outcomes;Patients;pharmacologic;pre-clinical;Pre-Clinical Model;prevent;promoter;Public Health;Quality of life;recombinase;Relapse;Research;Resistance;Resistance development;response;Role;Route;Signal Transduction;Solid;Specificity;success;Surface;syndecan;T-Lymphocyte;targeted treatment;Testing;Therapeutic;Therapeutic Agents;Therapeutic Effect;Therapeutic Monoclonal Antibodies;therapeutic target;Toxic effect;translational potential;treatment response;tumor;tumorigenic;United States;Work

PROJECT_TITLE: A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Gene Therapy;Genetics;Immunotherapy;Kidney Disease;Rare Diseases

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

PHR: PROJECT NARRATIVE Decades of research have led to the development of VEGF targeted agents for solid tumors; however, the true potenƟal of these agents is limited by systemic toxicity. VEGF also mediates T‐cell dysfuncƟonal cellular programs. This research project aims to both improve T‐cell ﬁtness and anƟ‐tumor acƟvity through CD70 targeted CAR‐T delivery of a VEGF‐blocking single chain variable fragment for renal cell carcinoma.

PI_NAMEs: LEICK, MARK  (contact)

PROGRAM_OFFICER_NAME: LIM, SUSAN E

PROJECT_TERMS: Achyrocline;Advisory Committees;angiogenesis;anti-cancer research;autocrine;Automobile Driving;B lymphoid malignancy;Biological Assay;Biology;blocking factor;Boston;Cancer Model;cancer therapy;CAR T cell therapy;Cardiovascular system;career development;CD19 gene;cell behavior;Cell Physiology;Cell secretion;Cell Survival;Cell Therapy;Cellular biology;Cellular immunotherapy;chimeric antigen receptor;chimeric antigen receptor T cells;clinical practice;Clinical Trials;cytokine release syndrome;cytotoxicity;Dana-Farber Cancer Institute;Data;Dependence;Development;Development Plans;Disease remission;Dose Limiting;Educational process of instructing;Endothelial Cells;Endothelium;Environment;exhaustion;Experimental Designs;FDA approved;fitness;Functional disorder;Future;General Hospitals;Goals;immunological synapse;improved;In Vitro;in vivo;Israel;KDR gene;Kidney;Knowledge;Malignant Neoplasms;Massachusetts;Mediating;Medical center;Mentors;Mentorship;Mission;Modeling;mouse model;neoplastic cell;Oncologist;Organ;Outcome;overexpression;paracrine;Paracrine Communication;Pathologic;Pathway interactions;Patient Care;Patients;Pediatric Hospitals;Persons;Pharmaceutical Preparations;pre-clinical;Pre-Clinical Model;prevent;programs;Proliferating;Proteins;receptor;Renal Cell Carcinoma;Reporter;Research;Research Personnel;Research Project Grants;response;Safety;Scientific Advances and Accomplishments;Side;side effect;Signal Pathway;Signal Transduction;Site;skills;Solid Neoplasm;Structure;symposium;systemic toxicity;T-Lymphocyte;targeted agent;targeted delivery;The Cancer Genome Atlas;Time;Tissues;Toxic effect;Training;Translational Research;Treatment Efficacy;tumor;Tumor Angiogenesis;Tumor Antigens;tumor growth;tumor microenvironment;Tumor Suppression;Vascular Endothelial Growth Factor Receptor-1;Vascular Endothelial Growth Factors;VEGFA gene

PROJECT_TITLE: Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma

STUDY_SECTION_NAME: Career Development Study Section (J)[NCI-J]